Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 23-25 April 2023 in Birmingham, UK, and brought hematology professionals together to discuss advances in the field.
It's been a jam-packed morning here in Glasgow at #IMS26! π΄σ §σ ’σ ³σ £σ ΄σ Ώ
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
It's our final day at #IMS26! π΄σ §σ ’σ ³σ £σ ΄σ Ώ π£
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
We're rounding out day 2 of #IMS26 by speaking with @FrancescoMaura4!
He covered topics including genomics and epigenetics, t(11;14) in treatment-naΓ―ve GPRC5D-negative #MultipleMyeloma, and the sequencing of CELMoDs. 𧬠π₯
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com π½οΈ π
The 63rd Annual Scientific Meeting of the British Society for Haematology
23–25 April 2023 | Birmingham, UK
The 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 23-25 April 2023 in Birmingham, UK, and brought hematology professionals together to discuss advances in the field.
It's been a jam-packed morning here in Glasgow at #IMS26! π΄σ §σ ’σ ³σ £σ ΄σ Ώ
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
It's our final day at #IMS26! π΄σ §σ ’σ ³σ £σ ΄σ Ώ π£
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
We're rounding out day 2 of #IMS26 by speaking with @FrancescoMaura4!
He covered topics including genomics and epigenetics, t(11;14) in treatment-naΓ―ve GPRC5D-negative #MultipleMyeloma, and the sequencing of CELMoDs. 𧬠π₯
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com π½οΈ π
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.